K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models

European Journal of Pharmacology

Volumn 689, Issue 1-3, 2012, Pages 132-138

  Sasaki, Yusuke ^a   Suzuki, Hideo ^a   Itoh, Shinsuke ^a   Yoshida, Hideo ^a   Kondo, Shoichi ^a   Inoue, Keisuke ^a   Tanabe, Sohei ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

Hindlimb blood flow; Intermittent claudication; K 134; Phosphodiesterase 3 inhibitor; Walking distance

Indexed keywords

6 [3 [3 CYCLOPROPYL 3 ( 2 HYDROXYCYCLOHEXYL)UREIDO]PROPOXY] 2 [1H]QUINOLINE; CILOSTAZOL; CLOPIDOGREL; K 134; LAURIC ACID; PHOSPHODIESTERASE III INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL RAT; FEMORAL ARTERY; GAIT DISORDER; HINDLIMB; LIMB BLOOD FLOW; MALE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RAT; TREADMILL EXERCISE; WALKING;

ANIMALS; DISEASE MODELS, ANIMAL; HINDLIMB; LAMENESS, ANIMAL; MALE; PERIPHERAL ARTERIAL DISEASE; PHOSPHODIESTERASE 3 INHIBITORS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; UREA;

EID: 84864277663     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.05.014     Document Type: Article

References (23)

1. H.G. Beebe, D.L. Dawson, B.S. Cutler, J.A. Herd, D.E. Strandness Jr.; E.B. Bortey, and W.P. Forbes A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial Arch. Intern. Med. 159 1999 2041 2050 (Pubitemid 29453592)
2. E.P. Brass, L.T. Cooper, R.E. Morgan, and W.R. Hiatt A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication J. Vasc. Surg. 55 2012 381 389
3. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
4. N. Corsico, A. Nardone, M.R. Lucreziotti, L.G. Spagnoli, D. Pesce, T. Aureli, M.E. Di Cocco, A. Miccheli, F. Conti, and E. Arrigoni Martelli Effect of propionyl-l-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study Cardiovasc. Drugs Ther. 7 1993 241 251 (Pubitemid 23174814)
5. D.L. Dawson, B.S. Cutler, M.H. Meissner, and D.E. Strandness Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial Circulation 98 1998 678 686 (Pubitemid 28387495)
6. D.L. Dawson, B.S. Cutler, W.R. Hiatt, R.W. Hobson 2nd, J.D. Martin, E.B. Bortey, W.P. Forbes, and D.E. Strandness Jr. A comparison of cilostazol and pentoxifylline for treating intermittent claudication Am. J. Med. 109 2000 523 530
7. T.M. Falconer, J.W. Eikelboom, G.J. Hankey, and P.E. Norman Management of peripheral arterial disease in the elderly: focus on cilostazol Clin. Interv. Aging 3 2008 17 23 (Pubitemid 351559800)
8. J. Goto, H. Araki, S. Otomo, and H. Aihara A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats Drugs. Exp. Clin. Res. 12 1986 917 921 (Pubitemid 17219231)
9. W.R. Hiatt Medical treatment of peripheral arterial disease and claudication N. Engl. J. Med. 344 2001 1608 1621 (Pubitemid 32479915)
10. S. Herzog, H. Sager, E. Khmelevski, A. Deylig, and W.D. Ito Collateral arteries grow from preexisting anastomoses in the rat hindlimb Am. J. Physiol. Heart Circ. Physiol. 283 2002 H2012 2020
11. N. Ishiwata, K. Noguchi, M. Kawanishi, Y. Asakura, M. Hori, A. Mitani, Y. Ito, K. Takahashi, H. Nishiyama, N. Shudo, S. Takahashi, K. Takahashi, N. Tsuruzoe, and S. Nakaike NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model Life Sci. 81 2007 970 978 (Pubitemid 47386005)
12. Y. Koga, Y. Kihara, M. Okada, Y. Inoue, S. Tochizawa, K. Toga, K. Tachibana, Y. Kimura, T. Nishi, and H. Hidaka 2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities Bioorg. Med. Chem. Lett. 8 1998 1471 1476 (Pubitemid 28281407)
13. A.V. Meru, S. Mittr, B. Thyagarajan, and A. Chugh Intermittent claudication Atherosclerosis 187 2006 221 237
14. S.R. Money, J.A. Herd, J.L. Isaacsohn, M. Davidson, B. Cutler, J. Heckman, and W.P. Forbes Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease J. Vasc. Surg. 27 1998 267 274
15. L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G. Fowkes, K. Bell, J. Caporusso, I. Durand-Zaleski, K. Komori, J. Lammer, C. Liapis, S. Novo, M. Razavi, J. Robbs, N. Schaper, H. Shigematsu, M. Sapoval, C. White, J. White, D. Clement, M. Creager, M. Jaff, E. Mohler 3rd, R.B. Rutherford, P. Sheehan, H. Sillesen, and K. Rosenfield Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Eur. J. Vasc. Endovasc. Surg. 33 Suppl. 1 2007 S1 S75
16. T. Ogawa, M. Hashimoto, Y. Niitsu, J.A. Jakubowski, Y. Tani, K. Otsuguro, F. Asai, and A. Sugidachi Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occlusive diseases Eur. J. Pharmacol. 612 2009 29 34
17. K. Orito, M. Kishi, H. Fujiki, T. Nakazawa, T. Imaizumi, Y. Kimura, T. Mori, and T. Kambe A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion J. Pharmacol. Toxicol. Methods 49 2004 25 29 (Pubitemid 37506052)
18. T. Sudo, K. Tachibana, K. Toga, S. Tochizawa, Y. Inoue, Y. Kimura, and H. Hidaka Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity Biochem. Pharmacol. 59 2000 347 356 (Pubitemid 30015963)
19. T. Uemura, H. Takamatsu, T. Kawasaki, M. Taniguchi, E. Yamamoto, Y. Tomura, W. Uchida, and K. Miyata Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats Eur. J. Pharmacol. 536 2006 154 161
20. K. Umemura, H. Ishihara, and M. Nakashima Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model Thrombosis Res. 80 1995 209 216
21. D. Vodnala, S. Rajagopalan, and R.D. Brook Medical management of the patient with intermittent claudication Cardiol. Clin. 29 2011 363 379
22. H. Yoshida, Y. Okamura, N. Watanabe, Y. Ikedam, and M. Handa Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation Thromb. Haemost. 105 2011 487 495
23. H. Yoshida, S. Itoh, T. Hara, Y. Sasaki, S. Kondo, T. Nakagawa, A. Asanuma, and S. Tanabe A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease Atherosclerosis 221 2012 84 90